Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells.
Claire
C
Morgan
Steve
S
Jeremiah
John
J
Wagstaff
D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D004164:Diphosphonates / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005452:Fluoresceins / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D000077557:Ibandronic Acid; D008297:Male; D010084:Oxidation-Reduction; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000032:analysis* / Q000378:metabolism; D013997:Time Factors; D014471:Umbilical Veins / Q000166:cytology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005452:Fluoresceins; D005456:Fluorescent Dyes; D017382:Reactive Oxygen Species; D000077557:Ibandronic Acid